The NumbersSo I look at the company as one transitioning from a speculative one (now that Plexxus deal is signed) to one where analysts start looking more closely at the bottom line? (not that they didn't before...) Below is a copy of part of the press release from Q1. I guess I' m wondering how this deal will affect future earnings. $4.25M for Q3 and Q4 is around $2M/quarter, with the potential to increase/decrease depending on conditions.
So this deal will not double revenue but will definitely give it a large boost. Any commentary on share appreciation from those more savvy than me. I am hoping for better Q2 numbers released in a couple of weeks,which will add fuel to the fire.
I guess I am asking - what is the compnay worth now (my typical response is - whatever people are willing to pay for it!). Is McWhirter close in his "guess" of $0.90, or is there more upside?
Q1 revenue was $3,157,659, a 54% increase from Q1 2020 revenue of $2,046,348. Included were antigen product revenues of $2,137,829 (Q1 2020 - $1,946,459), a recovery of 9.8%. QAPs revenues were $962,421, an increase of 3,585% from Q1 2020 sales of $26,114, a prior year quarter that contained no REDx™ (IVD) and few PROCEEDx™ (RUO) branded QAPs sales. Finally, royalties were $57,409 (Q1 2020 - $73,775). Q1 sales were most influenced by the broadening diagnostics industry uptake of Microbix’s COVID-19 related QAPs, especially REDx™FLOQ® and PROCEEDx™FLOQ®, followed by the start of a broad-based recovery in antigen sales.